Private company

Rapid Therapeutic Science Laboratories, Inc.

Rapid Therapeutic Science Laboratories, Inc. is an American pharmaceutical preparations company, incorporated in Nevada.¹ It is headquartered in De Leon, Texas.¹

Last updated Oct 20, 2026.

Overview

IndustryPharmaceutical Preparations¹
HeadquartersDe Leon, Texas¹
Incorporated inNV²
Business address558 County Road 472, De Leon, Tx 76444²
Filer categoryNon-accelerated filer, Smaller reporting company²

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

-100.0%Revenue growth, 2022³

-$1.2MFree cash flow³

Financial statements

Revenue⁴⁵⁶⁷³$0 in 2022

Gross profit⁶⁷³$0 in 2022

Operating income⁸-$21.6K in 2017+80% since 2016

Net income⁸⁴⁵⁶⁷³-$1.8M in 2022+14831% since 2016

Fiscal year	2016	2017	2018	2019	2020	2021	2022
Revenue		$0⁴	$0⁵	$0⁶	$130.9K⁷	$534³	$0³
Cost of revenue				$0⁶	$19.4K⁷	$200³	$0³
Gross profit				$0⁶	$111.5K⁷	$334³	$0³
Operating income	-$12.0K⁸	-$21.6K⁸
Interest		$0⁴	$28.6K⁵	$180.5K⁶	$58.0K⁷	$1.3M³	$1.9M³
Income before tax						-$2.9M³	-$1.8M³
Income tax					$0⁷	$0³	$0³
Net income	-$12.0K⁸	-$21.6K⁴	-$2.6M⁵	-$348.8K⁶	-$2.1M⁷	-$2.9M⁷	-$1.8M³
Earnings per share	$0.00⁸	-$0.01⁸				-$0.38³	-$0.23³
Shares (weighted, basic)						7.6M shares³	7.7M shares³

Total assets⁸⁴⁵⁶⁷³$2.3M in 2022+22473% since 2016

Total liabilities⁸⁴⁵⁶⁷³$5.4M in 2022+47750% since 2016

Shareholders’ equity⁸⁴⁵⁷³-$3.1M in 2022+243615% since 2016

Cash⁴⁵⁶⁷³$0 in 2022

Fiscal year	2016	2017	2018	2019	2020	2021	2022
Cash	$9.2K⁴	$7.4K⁵	$12.3K⁶	$136.2K⁷	$499.1K⁷	$192.5K³	$0³
Inventory						$175.0K³	$175.0K³
Current assets	$10.0K⁸	$7.4K⁴	$22.5K⁵	$1.3K⁶	$685.9K⁷	$419.2K³	$233.2K³
Property, plant and equipment						$1.2M³	$1.5M³
Intangible assets						$170.1K³	$170.1K³
Total assets	$10.0K⁸	$7.4K⁴	$26.2K⁵	$1.3K⁶	$1.5M⁷	$2.2M³	$2.3M³
Current liabilities	$11.3K⁸	$30.3K⁴	$688.9K⁵	$969.8K⁶	$1.2M⁷	$3.1M³	$5.0M³
Total liabilities	$11.3K⁸	$30.3K⁴	$2.9M⁵	$3.2M⁶	$1.5M⁷	$3.6M³	$5.4M³
Retained earnings						-$8.5M³	-$10.3M³
Shareholders’ equity	-$1.3K⁸	-$22.9K⁴	-$2.9M⁵	-$1.4M⁷	-$11.2K⁷	-$1.4M³	-$3.1M³
Shares outstanding	2.7M shares¹¹	2.7M shares⁸	1.2M shares⁴	1.2M shares⁵	180.9M shares⁷	7.7M shares³	7.8M shares³

Cash from operations⁸⁷³-$1.2M in 2022+10621% since 2016

Capital spending⁷³$39.2K in 2022−63% since 2020

Free cash flow⁷³-$1.2M in 2022−35% since 2020

Fiscal year	2016	2017	2020	2021	2022
Cash from operations	-$10.7K⁸	-$21.8K⁸	-$1.7M⁷	-$2.2M³	-$1.2M³
Stock-based compensation				$20.0K³	$20.0K³
Capital spending			$106.7K⁷	$292.5K³	$39.2K³
Free cash flow			-$1.8M	-$2.5M	-$1.2M
Cash from investing				-$292.5K³	-$39.2K³
Cash from financing				$2.2M³	$998.4K³

Compare Rapid Therapeutic Science Laboratories, Inc. with another company

Corporate structure

Rapid Therapeutic Science Laboratories, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Rapid Therapeutic Science Laboratories, Inc.

ARMISTICE CAPITAL, LLC Filed SC 13G on Rapid Therapeutic Science Laboratories, Inc., latest Feb 14, 2024

Rapid Therapeutic Science Laboratories, Inc. De Leon, Texas

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Rapid Therapeutic Science Laboratories, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Item	Latest	A year before	Change
Property and equipment, before depreciation	$1.6M³ Dec 31, 2022	$1.2M³ Dec 31, 2021	+28.8%
Property and equipment, net	$1.5M³ Dec 31, 2022	$1.2M³ Dec 31, 2021	+27.5%
Operating-lease assets (leased space)	$340.1K³ Dec 31, 2022	$425.2K³ Dec 31, 2021	−20.0%

Investments

Item	Latest	A year before	Change
Cash and cash equivalents	$0³ Dec 31, 2022	$192.5K³ Dec 31, 2021	−100.0%

Intangibles and goodwill

Item	Latest	A year before	Change
Intangible assets, net (excluding goodwill)	$170.1K³ Dec 31, 2022	$170.1K³ Dec 31, 2021	0%

Inventory

Item	Latest	A year before	Change
Inventory, total	$175.0K³ Dec 31, 2022	$175.0K³ Dec 31, 2021	0%

Leadership

Who has led Rapid Therapeutic Science Laboratories, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

President

Chief financial officer

Chief operating officer

Ryan Casey Johnson2020

20202025

Chief executive officerDonal Ray Schmidt Jr. Jan 25, 2021 to Dec 28, 2021¹²
Chief executive officerBrent Willson Feb 21, 2018 to Feb 21, 2018¹³
PresidentDonal Ray Schmidt Jr. Jan 25, 2021 to Feb 4, 2021¹²
PresidentBrent Willson Feb 21, 2018 to Feb 21, 2018¹³
Chief financial officerD. Hughes Watler Dec 16, 2020 to Dec 16, 2020¹⁴
Chief financial officerSteve Bond Feb 21, 2018 to Feb 21, 2018¹⁵
Chief operating officerRyan Casey Johnson Nov 18, 2020 to Nov 18, 2020¹⁶

Board members and other officers (7)

Board memberDonal Ray Schmidt Jr. Jan 25, 2021 to Dec 28, 2021¹²
Board memberScott Suggs Justin Aug 5, 2021 to Dec 30, 2021¹⁷
Board memberHenry Anthony Punzi Aug 27, 2021 to Aug 27, 2021¹⁸
Board memberRyan Casey Johnson Nov 18, 2020 to Nov 18, 2020¹⁶
Board memberD. Hughes Watler Dec 16, 2020 to Dec 16, 2020¹⁴
Board memberBrent Willson Feb 21, 2018 to Feb 21, 2018¹³
Board memberSteve Bond Feb 21, 2018 to Feb 21, 2018¹⁵

Former names

Holly Brothers Pictures, Inc.Jun 7, 2017 to Jan 21, 2020²
PowerMedChairsMay 23, 2013 to May 9, 2017²

Timeline

Dec 6, 20238-K Change of auditor; Executive or director change¹⁹
Aug 23, 20238-K Entered a material agreement; New debt or obligation; Unregistered sale of shares²⁰
Jul 14, 20238-K Change of auditor²¹
May 31, 20228-K Entered a material agreement; New debt or obligation; Unregistered sale of shares²²
Mar 31, 20228-K Change to shareholders' rights; Bylaws or fiscal year changed; Regulation FD disclosure²³
Feb 1, 20228-K Entered a material agreement; New debt or obligation; Unregistered sale of shares²⁴
Jan 21, 20228-K Entered a material agreement; New debt or obligation; Unregistered sale of shares²⁵
Jan 18, 20228-K Executive or director change; Shareholder vote²⁶
Oct 12, 20218-K Regulation FD disclosure²⁷
Jan 25, 2021New chief executive Donal Ray Schmidt Jr. becomes CEO¹²
Feb 21, 2018New chief executive Brent Willson becomes CEO¹³

Filings

28 filings to the SEC since October 2021: 2 annual reports, 6 quarterly reports, 9 major events, 3 insider forms, 1 large holders, 7 other. The latest 20:

The 28 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

ARMISTICE CAPITAL, LLCSC 13G, 1 filing Feb 14, 2024²⁸

SEC filer profile

How Rapid Therapeutic Science Laboratories, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

Name on EDGARRapid Therapeutic Science Laboratories, Inc.¹
CIK0001575659
Employer ID (EIN)46-2111820¹
Filer statusNon-accelerated filer<br>smaller reporting company¹
Incorporated inNevada¹
Fiscal year endsDecember 31¹
Industry code (SIC)2834 Pharmaceutical Preparations¹
SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance¹
Business address558 County Road 472, De Leon, TX 76444¹
Phone800-497-6059¹
Shares outstanding8,832,251 as of Aug 14, 2023¹⁰
Public float$5.5M as of Jun 30, 2022³
On EDGAR sinceMay 23, 2013¹
Filings146 in all: 8-K (33), 10-Q (31), 10-K (9), 3 (8), NT 10-Q (7), 4 (6), DEF 14C (5), NT 10-K (5)¹
All 26 form types
PRE 14C (5), S-1/A (5), CORRESP (4), SC 13D (4), D (3), SC 13G (3), UPLOAD (3), 3/A (2), 8-K/A (2), DEFA14C (2), S-1 (2), 10-K/A (1), 10-KT (1), 15-12G (1), 424B3 (1), 8-A12G (1), EFFECT (1), RW (1)
Latest filingsAnnual report (10-K) Mar 30, 2023
Quarterly report (10-Q) Aug 14, 2023
Latest 8-K (8-K) Dec 6, 2023

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARRapid Therapeutic Science Laboratories, Inc. filings on SEC EDGAR
2
SEC EDGARRapid Therapeutic Science Laboratories, Inc. filings on SEC EDGAR
3
SEC EDGARRapid Therapeutic Science Laboratories, Inc. 10-K for fiscal 2022
4
SEC EDGARRapid Therapeutic Science Laboratories, Inc. 10-K for fiscal 2017
5
SEC EDGARRapid Therapeutic Science Laboratories, Inc. 10-K for fiscal 2018
6
SEC EDGARRapid Therapeutic Science Laboratories, Inc. 10-K for fiscal 2019
7
SEC EDGARRapid Therapeutic Science Laboratories, Inc. 10-K for fiscal 2020
8
SEC EDGARRapid Therapeutic Science Laboratories, Inc. 10-K for fiscal 2016
9
SEC EDGARRapid Therapeutic Science Laboratories, Inc. 10-Q for fiscal 2023
10
SEC EDGARRapid Therapeutic Science Laboratories, Inc. 10-Q for fiscal 2023
11
SEC EDGARRapid Therapeutic Science Laboratories, Inc. 10-K for fiscal 2016
12
SEC EDGARDonal Ray Schmidt Jr., Chief executive officer
13
SEC EDGARBrent Willson, Chief executive officer
14
SEC EDGARD. Hughes Watler, Chief financial officer
15
SEC EDGARSteve Bond, Chief financial officer
16
SEC EDGARRyan Casey Johnson, Chief operating officer
17
SEC EDGARScott Suggs Justin, Board member
18
SEC EDGARHenry Anthony Punzi, Board member
19
SEC EDGARChange of auditor; Executive or director change
20
SEC EDGAREntered a material agreement; New debt or obligation; Unregistered sale of shares
21
SEC EDGARChange of auditor
22
SEC EDGAREntered a material agreement; New debt or obligation; Unregistered sale of shares
23
SEC EDGARChange to shareholders' rights; Bylaws or fiscal year changed; Regulation FD disclosure
24
SEC EDGAREntered a material agreement; New debt or obligation; Unregistered sale of shares
25
SEC EDGAREntered a material agreement; New debt or obligation; Unregistered sale of shares
26
SEC EDGARExecutive or director change; Shareholder vote
27
SEC EDGARRegulation FD disclosure
28
SEC EDGARARMISTICE CAPITAL, LLC SC 13G on Rapid Therapeutic Science Laboratories, Inc.